2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2944

Use of Muscle Biopsies for the Diagnosis of Systemic Vasculitis in a Rheumatology Service

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2442

Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2888

Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2893

Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2635

Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2834

Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2235

Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2546

Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2744

Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2244

Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2972

Vaccination and Risk of Childhood IgA Vasculitis (Henoch–Schönlein): A Case-Crossover Analysis

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2385

Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2167

Validation of the Earp Questionnaire: Detection of Psoriatic Arthritis in the Spanish Population

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2467

Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2384

Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA 2 Deficiency

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].